市場調查報告書
商品編碼
1154880
宏基因組學全球市場規模、份額、行業趨勢分析報告按工作流程、按產品(試劑盒/試劑、測序/數據分析服務、軟件)、技術、應用、地區、展望和預測2022-2028Global Metagenomics Market Size, Share & Industry Trends Analysis Report By Workflow, By Product (Kits & Reagents, Sequencing & Data Analytics Services and Software), By Technology, By Application, By Regional Outlook and Forecast, 2022 - 2028 |
到 2028 年,全球宏基因組學市場規模預計將達到 32 億美元,預測期內復合年增長率為 13.6%。
最近的研究使用“鳥槍法”或 PCR 定向測序從樣本群落的所有成員中獲取幾乎無偏差的所有基因樣本。宏基因組學一詞源於這樣一種觀念,即可以像研究單個基因組一樣研究一組已排序的環境基因。作為 DNA 的來源,常規測序從相同細胞的培養開始。然而,早期的宏基因組學研究表明,在某些棲息地,無法培養廣泛的微生物群落,因此無法對其進行測序。
因此,發現了多個與已知養殖物種不對應的 16S rRNA 序列,揭示了許多非分離生物的存在。這些對直接從環境中提取的核醣體 RNA 基因的研究表明,基於培養的方法可以檢測到樣品中不到 1% 的細菌和古細菌。大量以前未被認識的微生物的發現極大地促進了宏基因組學分析的傳播。
COVID-19 影響分析
自 COVID-19 出現以來,生命科學和生物技術行業的主要參與者都在尋求跟蹤、診斷和治療 COVID-19 的解決方案。宏基因組學分析對於病毒發現和跟蹤至關重要。已經引入了多種序列監測解決方案和平台以進行有效的感染診斷。例如,2021 年 5 月,牛津大學與 Oracle 建立了戰略合作關係,以開發強大的基於雲的基因組測序和分析平台,以降低冠狀病毒感染的風險。由於對 COVID-19 藥物和疫苗發現的特殊需求,宏基因組學市場的經濟活動正在加速。
市場增長因素
NGS平台的技術不斷進步
測序技術的持續進步促成了高效、便攜且用戶友好的 NGS 平台的開發,這些平台可以提供快速準確的結果並縮短周轉時間。此類產品和技術的推出讓玩家獲得了立竿見影的競爭優勢,因此主要玩家都在加大研發投入,以提高市場地位和份額。由於技術改進,許多新的生物信息學工具被添加到宏基因組學市場,增加了市場收入。
大數據NGS數據分析
全基因組測序過程中生成的數據量通常為 TB 級。數據管理是基於 NGS 的宏基因組測序的最終用戶面臨的主要挑戰。由於數據格式的差異以及不同 NGS 平台的數據輸出缺乏行業標準,數據保留要求可能非常複雜。通過將大數據技術和人工智能應用於NGS分析和工作流程管理,NGS運行的良率得到顯著提高。隨著測序技術的發展,測序過程中收集的數據量也在不斷增加。
市場約束
發展中國家的最終用戶預算限制
在發展中國家,大部分學術研究和開發都依賴於其他資金。即使 NGS 測序儀的成本下降,它們仍然非常昂貴。 NovaSeq 5000 和 6000 是 Illumina 最強大的測序儀,在美國的售價在數百到數萬美元之間。
產品概覽
宏基因組學市場按產品細分為試劑盒和試劑、測序和數據分析服務以及軟件。試劑盒和試劑部分在 2021 年的宏基因組市場中佔據了最高的收入份額。這是因為在測序的實驗樣品製備階段使用了不同的化學品。 F. Hoffmann-La Roche Ltd、Thermo Fisher Scientific 和 Illumina Inc. 等知名公司提供多種試劑以滿足您的測序需求。
技術展望
宏基因組學市場按技術細分為鳥槍法測序、16S 測序、全基因組測序等。 2021 年,全基因組測序部分在宏基因組學市場中佔據了相當大的收入份額。全基因組測序,也稱為全基因組測序,是一種一次性確定生物體基因組的所有或幾乎所有 DNA 序列的方法。
工作流程概覽
宏基因組學市場按工作流程細分為預測序、測序和數據分析。 2021 年,預測序部分在宏基因組學市場中佔據了重要的收入份額。預測序注意事項包括文庫大小、讀取持續時間和類型(單端或雙端)以及測序深度的選擇。測序後決策包括預處理步驟、參考庫和映射技術的選擇。
應用展望
根據在環境、臨床診斷、藥物發現、生物技術、食品和營養等領域的應用,宏基因組學市場分為兩部分。到 2021 年,環境部門將在宏基因組學市場中佔據最大的收入份額。宏基因組學在農業和環境保護方面的研究領域正在迅速擴大。宏基因組學是一種通過序列分析和基因篩選了解特定環境微生物的新方法。
區域展望
按地區劃分,在北美、歐洲、亞太地區和 LAMEA 進行了分析。到 2021 年,北美部分將在宏基因組學市場中佔據最大的收入份額。這種優勢可能是由於研發資金的增加和測序技術的進步,該地區出現了大公司。公司與學術機構之間的合作是該地區最重要的商業戰略之一。
The Global Metagenomics Market size is expected to reach $3.2 billion by 2028, rising at a market growth of 13.6% CAGR during the forecast period.
The study of genetic material extracted directly from samples collected is known as metagenomics. This expansive field is also known as environmental genomics, ecogenomics, and community genomics. While conventional microbiology, microbial genome sequencing, and genomics rely on produced clonal cultures, the early environmental genetic analysis relied on cloning certain genes (typically the 16S rRNA gene) to generate a profile of variety in a wild sample.
It demonstrated that cultivation-based approaches have missed the large bulk of microbial biodiversity. Metagenomics has the potential to transform knowledge of the whole living universe as a result of its ability to uncover the hitherto hidden diversity of microorganisms. As the cost of DNA sequencing continues to decline, metagenomics now enables the investigation of microbial ecology on a much larger scale and in greater depth than ever before.
Recent studies use "shotgun" or PCR-directed sequencing to obtain largely unbiased samples of all genes from all sampled community members. The term metagenome referred to the concept that a collection of sequenced environmental genes might be studied similarly to a single genome. As a source of DNA, conventional sequencing begins with a culture of identical cells. However, early metagenomic investigations indicated that broad groups of microbes in several habitats could not be cultivated and hence cannot be sequenced.
Multiple 16S rRNA sequences that do not correspond to any known cultured species have been discovered, indicating the existence of numerous non-isolated organisms. These surveys of ribosomal RNA genes extracted directly from the environment demonstrated that cultivation-based approaches detect less than one percent of the bacterial and archaeal organisms in a sample. The discovery that the great majority of microorganisms were previously unrecognized is largely responsible for the growing popularity of metagenomics.
COVID-19 Impact Analysis
Since the emergence of COVID-19, important players in the life sciences and biotechnology industries have sought solutions for COVID-19 tracking, diagnosis, and treatment. The analysis of metagenomics is vital for the discovery and tracking of the virus. Diverse sequencing monitoring solutions and platforms are being implemented for efficient infection diagnosis. In May 2021, for instance, Oxford University and Oracle established strategic cooperation to develop a robust cloud-based genomic sequencing and analysis platform to reduce the risk of coronavirus infection. Due to the exceptional demand for COVID-19 medication and vaccine discovery, economic activity in the metagenomics market is accelerating.
Market Growth Factors
Constant Technological Advancements In NGS Platforms
Continuous technological advancements in sequencing techniques have enabled the development of efficient, portable, and user-friendly NGS platforms that are capable of delivering speedy and accurate results and have a reduced turnaround time. The introduction of such products and technology offers players an immediate competitive advantage; hence, leading companies are investing more in R&D to increase their market positions and shares. Many new bioinformatics tools have been added to the metagenomics market as a result of technical improvements, which have increased the market's revenue.
NGS Data Analysis With Big Data
The amount of data generated during whole-genome sequencing is often at the terabyte level. For end-users of NGS-based metagenomic sequencing, data management is a significant challenge. Due to differences in data formats and the lack of an industry-wide standard for data output from different NGS platforms, data storage requirements can be rather complex. The application of big data technologies and AI for NGS analysis and workflow management has considerably boosted the yield of NGS runs. With developments in sequencing technology, the quantity of data collected during a sequencing run likewise grows.
Market Restraining Factors
Constrained End-User Budgets In Developing Nations
Academic research and development are almost entirely reliant on financial support from other sources in nations that are still considered to be developing. NGS sequencers continue to be prohibitively costly even though the cost of NGS sequencing has come down. The NovaSeq 5000 and 6000 are Illumina's two most sophisticated sequencing systems, and their prices range from hundreds to tens of thousands of US dollars.
Product Outlook
Based on the Product, the Metagenomics Market is segmented into Kits & Reagents, Sequencing & Data Analytics Services, and Software. The kits & reagents segment acquired the highest revenue share in the metagenomics market in 2021. It is because, during the experimental sample preparation phase of sequencing, a variety of chemicals are utilized. Established firms such as F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, and Illumina Inc. offer an extensive selection of reagents to meet the needs of sequencing.
Technology Outlook
On the basis of Technology, the Metagenomics Market is divided into Shotgun Sequencing, 16S Sequencing, Whole Genome Sequencing, and Others. The whole genome sequencing segment recorded a substantial revenue share in the metagenomics market in 2021. Whole genome sequencing, also known as whole genome sequencing, complete genome sequencing, and entire genome sequencing, is the method of determining all or almost all of the DNA sequences of an organism's genome at once.
Workflow Outlook
By Workflow, the Metagenomics Market is classified into Pre-sequencing, Sequencing, and Data Analysis. The pre-sequencing segment registered a significant revenue share in the metagenomics market in 2021. Pre-sequencing considerations include a selection of library size, read duration and type (single or paired-end), and sequencing depth. Post-sequencing decisions consist of choosing pre-processing stages, a reference library, and a mapping technique.
Application Outlook
Based on the Application, the Metagenomics Market is bifurcated into Environmental, Clinical Diagnostics, Drug Discovery, Biotechnology, Food & Nutrition, and Others. The environmental segment acquired the largest revenue share in the metagenomics market in 2021. The space for metagenomics research in agriculture and environmental protection is expanding fast. Metagenomics is a novel approach to comprehending microorganisms from a certain environment by sequencing analysis or gene screening.
Regional Outlook
Region-wise, the Metagenomics Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment garnered the largest revenue share in the metagenomics market in 2021. This dominance can be attributed to the presence of major corporations in the region with increasing R&D funding and technological advances in sequencing. Collaboration between businesses and academic institutions is one of the region's most important business strategies.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Illumina, Inc., PerkinElmer, Inc., Thermo Fisher Scientific, Inc., Novogene Co., Ltd., Promega Corporation, Qiagen N.V., Takara Bio, Inc. (Takara Holdings Inc.), Oxford Expression Technologies Ltd., and F. Hoffmann-La Roche Ltd.
Strategies deployed in Metagenomics Market
Jun-2022: Oxford Nanopore unveiled a novel protocol for the rapid metagenomic characterization of DNA and RNA viruses. The protocol represents a simple metagenomic workflow that can be utilized to recognize DNA and RNA viruses. Moreover, this method has been applied in human clinical specimens to describe the pathogen presently known as the monkeypox virus.
Jun-2022: Illumina completed the acquisition of IDbyDNA, a company producing metagenomic technology. Under this acquisition, IDbyDNA delivers a respiratory pathogen panel enrichment kit that recognizes more than 280 pathogens, including SARS-CoV-2, and more than 1,200 antimicrobial resistance alleles. Moreover, it operates on Illumina's NextSeq 550 sequencing system and employs IDbyDNA's Explify analysis software.
Mar-2022: QIAGEN signed a two-year agreement with National Health Service, a publicly funded healthcare system in England. Through this agreement, Human Gene Mutation Database would be utilized at seven sites to help understand genomic data from next-generation sequencing. Additionally, NGS data from over 2.5 million clinical cases are now researched and diagnosed by QIAGEN Digital Insights solutions
Nov-2021: Novogene introduced single-cell sequencing services. The service offers an on-site service for Novogene Japan K.K. to support consumers in optimizing their single-cell preparation work. Moreover, it delivers the flexibility for investigators to enjoy a reliable and hassle-free experience of an end-to-end sequencing solution for their single-cell analysis from experimental project design, library preparation, cell barcoding, bioinformatic analysis, and sequencing.
Jun-2021: Illumina came into a partnership with Microba Life Sciences, world-leading technology for measuring the human gut microbiome. Together, the companies aimed to obtain Illumina's revolutionary NGS tools and Microba's high-quality proprietary gut microbiome analysis platform to develop the precise metagenomic data that researchers need to boost findings. Moreover, Microba Life Sciences is growing human health with new solutions produced from the human gut microbiome.
Mar-2021: NovogeneAIT Genomics expanded its geographical footprint by establishing a single-cell sequencing lab in Singapore. This expansion includes a facility to deliver an entire end-to-end solution of the single-cell gene expression services such as single-cell experimental design, sequencing, data analysis, and single-cell capture. Additionally, the single-cell lab would deliver its services utilizing the 10x Illumina platforms and Genomics Chromium System.
Mar-2020: Illumina formed a partnership with IDbyDNA, a metagenomics technology enterprise. Through this partnership, the companies aimed to boost NGS adoption for clinical infectious sickness testing.
Oct-2019: Novogene expanded its geographical footprint by increasing its capacity to Cambridge Science Park. This expansion contains plant and animal genome sequencing, metagenome sequencing, human genome sequencing, transcriptome sequencing, and lanes sequencing. Moreover, the Novogene Cambridge Sequencing Centre is now able of performing more than 280,000 human WGS analyses every year.
Market Segments covered in the Report:
By Workflow
By Product
By Technology
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures